Core Laboratories N.V. (CLB) Stake Raised by FDx Advisors Inc.

FDx Advisors Inc. lifted its position in shares of Core Laboratories N.V. (NYSE:CLB) by 15.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 16,402 shares of the oil and gas company’s stock after buying an additional 2,167 shares during the quarter. FDx Advisors Inc.’s holdings in Core Laboratories N.V. were worth $1,619,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. WCM Investment Management CA increased its position in shares of Core Laboratories N.V. by 7.3% during the second quarter. WCM Investment Management CA now owns 4,433,175 shares of the oil and gas company’s stock worth $448,948,000 after buying an additional 303,073 shares during the period. Vanguard Group Inc. increased its position in shares of Core Laboratories N.V. by 1.6% during the second quarter. Vanguard Group Inc. now owns 3,672,865 shares of the oil and gas company’s stock worth $371,950,000 after buying an additional 56,807 shares during the period. Sustainable Growth Advisers LP increased its position in shares of Core Laboratories N.V. by 36.9% during the second quarter. Sustainable Growth Advisers LP now owns 2,345,271 shares of the oil and gas company’s stock worth $237,505,000 after buying an additional 632,263 shares during the period. Kayne Anderson Rudnick Investment Management LLC increased its position in shares of Core Laboratories N.V. by 1.3% during the second quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,702,000 shares of the oil and gas company’s stock worth $172,364,000 after buying an additional 22,276 shares during the period. Finally, BlackRock Inc. boosted its stake in Core Laboratories N.V. by 3,736.4% during the first quarter. BlackRock Inc. now owns 1,598,608 shares of the oil and gas company’s stock worth $184,672,000 after acquiring an additional 1,556,938 shares in the last quarter.

Core Laboratories N.V. (CLB) opened at $104.30 on Tuesday. Core Laboratories N.V. has a 12 month low of $86.55 and a 12 month high of $125.83. The firm has a market cap of $4,653.13, a price-to-earnings ratio of 57.60 and a beta of 1.57. The company has a quick ratio of 1.81, a current ratio of 2.18 and a debt-to-equity ratio of 1.53.

Core Laboratories N.V. (NYSE:CLB) last released its quarterly earnings data on Monday, October 23rd. The oil and gas company reported $0.48 earnings per share for the quarter, beating analysts’ consensus estimates of $0.44 by $0.04. Core Laboratories N.V. had a net margin of 12.06% and a return on equity of 52.89%. The firm had revenue of $166.20 million for the quarter, compared to analyst estimates of $160.94 million. During the same period last year, the firm earned $0.38 earnings per share. The business’s quarterly revenue was up 1.4% compared to the same quarter last year. equities research analysts anticipate that Core Laboratories N.V. will post 1.99 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, November 21st. Shareholders of record on Friday, October 20th will be paid a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a dividend yield of 2.11%. The ex-dividend date is Thursday, October 19th. Core Laboratories N.V.’s dividend payout ratio (DPR) is 126.44%.

CLB has been the topic of several research analyst reports. Loop Capital cut their target price on shares of Core Laboratories N.V. from $125.00 to $115.00 and set a “buy” rating on the stock in a research note on Wednesday, October 25th. Credit Suisse Group raised shares of Core Laboratories N.V. from a “neutral” rating to an “outperform” rating and set a $110.00 target price on the stock in a research note on Thursday, August 24th. They noted that the move was a valuation call. Royal Bank Of Canada cut their target price on shares of Core Laboratories N.V. from $115.00 to $112.00 and set an “outperform” rating on the stock in a research note on Thursday, September 7th. Piper Jaffray Companies set a $97.00 target price on shares of Core Laboratories N.V. and gave the stock a “hold” rating in a research note on Wednesday, July 26th. Finally, ValuEngine lowered shares of Core Laboratories N.V. from a “hold” rating to a “sell” rating in a research note on Friday, September 1st. Four investment analysts have rated the stock with a sell rating, seven have given a hold rating and six have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $108.64.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by Stock Observer and is the sole property of of Stock Observer. If you are reading this news story on another publication, it was illegally copied and reposted in violation of United States & international trademark and copyright laws. The legal version of this news story can be viewed at https://www.thestockobserver.com/2017/11/14/core-laboratories-n-v-clb-stake-raised-by-fdx-advisors-inc.html.

Core Laboratories N.V. Company Profile

Core Laboratories N.V. provides reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company operates through three segments: Reservoir Description, Production Enhancement and Reservoir Management. The Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid and gas samples.

Want to see what other hedge funds are holding CLB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Core Laboratories N.V. (NYSE:CLB).

Institutional Ownership by Quarter for Core Laboratories N.V. (NYSE:CLB)

Receive News & Ratings for Core Laboratories N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories N.V. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply